Status:
UNKNOWN
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.
Lead Sponsor:
Beneficência Portuguesa de São Paulo
Conditions:
Quality of Life
Breast Neoplasm Female
Eligibility:
FEMALE
18+ years
Brief Summary
Assess the quality of life in patients with hormone receptor positive, human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line (patients with new metastas...
Detailed Description
The main objective of the study is to assess the quality of life using the EORTC-QLQ-C30 (EORTC Quality of Life Questionnaire) and the EORTC-QLQ-BR23 (EORTC Quality of Life Questionnaire - Breast Canc...
Eligibility Criteria
Inclusion
- Patients who agree to participate by signing a document of free and informed consent (ICF), indicating that the research participant was informed about all relevant aspects of the study;
- Female patients ≥ 18 years of age;
- Patients diagnosed with hormone receptor positive, human epidermal growth factor receptor-type 2 -negative metastatic breast cancer; in first-line treatment (metastatic de novo disease or patients with recurrence during adjuvant endocrine therapy).
- First-line treatment can be considered as cytotoxic chemotherapy, isolated endocrine therapy or endocrine therapy in combination with 4/6 cyclin inhibitors.
- Patients on treatment for at least three (3) months and no more than eighteen (18) months.
- Have performance status Eastern Cooperative Oncology Group (ECOG scale) of 0-2.
- Do not present other concomitant neoplasms.
Exclusion
- Patients who refuse to participate.
- Illiterate patients, with low levels of education or cognitive deficits that make it difficult to answer the questions of the data collection instrument.
- Patients with life expectancy \<3 months.
- Treatment with any product under investigation during the last 28 days.
Key Trial Info
Start Date :
July 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2022
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT05287139
Start Date
July 14 2021
End Date
July 30 2022
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Pérola Byington
São Paulo, Brazil